Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Long-term results of the BELIEVE study: luspatercept in patients with beta-thalassemia

Maria Domenica Cappellini • 10 Jun 2022
EHA 2022
Non-Malignant Thalassemia Luspatercept
BELIEVE

Maria Domenica Cappellini, MD, University of Milan, Milan, Italy, shares some long-term results from the Phase III BELIEVE study (NCT02604433) evaluating the safety and efficacy of luspatercept in patients with transfusion-dependent beta-thalassemia. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Disclosures

Member of the advisory board for Celgene and BMS

More from Maria Domenica Cappellini

11:42
Thalassemia highlights at ASH 2023: novel therapies, trial updates & the value of precision medicine
Kevin Kuo et al. • 11 Dec 2023
3:38
Looking to the future in the treatment of beta thalassemia
Maria Domenica Cappellini • 8 Dec 2023
8:38
Treating transfusion dependent and independent beta-thalassemia, and BELIEVE/BEYOND trial updates
Maria Domenica Cappellini • 8 Dec 2023
1:00
Luspatercept and mitapivat for the treatment of patients with beta-thalassemia
Maria Domenica Cappellini • 27 Oct 2023

Related Videos

2:38
Treosulfan vs busulfan conditioning in pediatric patients with non-malignant diseases
Rita Beier • 15 Apr 2024
2:18
A global view of transfusion-dependent thalassemia: standard of care, outcomes, and unmet needs
Ali Taher • 15 Apr 2024
1:24
The future of CAR T-reg cells: organ transplantation & autoimmune disease
Zinaida Good • 9 Apr 2024
1:23
Developing a PRO collection tool for patients with SCD: key themes which are important to patients
Nirmish Shah • 8 Dec 2023
The content of VJHemOnc is intended for healthcare professionals